In a major move within the pharmaceutical sector, Sanofi India has initiated the sale of its flagship insulin brand, Lantus. The French drugmaker is reportedly in talks with several leading domestic pharmaceutical companies, including Glenmark, Dr. Reddy’s Laboratories, and Emcure Pharma, for the potential acquisition.
Lantus Sale Gains Momentum Amid Strategic Shift
According to sources familiar with the discussions, Sanofi has fixed a base price of ₹2,000 crore for Lantus, which marks a notable reduction from its earlier valuation of around ₹3,000 crore. This signals a more realistic pricing strategy from the company in order to attract strong bids from India’s top pharma players.
“The sale of Lantus is part of Sanofi’s broader strategic re-alignment,” said a person involved in the deal.
Indian Pharma Giants Show Strong Interest
The deal is drawing interest from prominent domestic players, all eager to expand their footprint in the insulin and diabetes care market in India — a space that is growing steadily with increasing demand.
Sanofi’s Lantus has long been a top-selling insulin brand in India, known for its quality and market presence. By offloading this asset, Sanofi is looking to streamline its portfolio and possibly reallocate resources to other areas of growth or innovation.
Big Pharma Moves, Big Pharma Gains?
If successful, this transaction will mark one of the biggest deals in India’s pharma space involving a global brand. It could also open up new opportunities for Indian companies to dominate a critical therapeutic segment.
The Lantus sale could reshape market dynamics in India’s diabetes care sector.
With negotiations underway and multiple bidders showing interest, the deal is expected to progress in the coming months. All eyes are now on which Indian pharma giant will secure this high-value brand.
